Common GLP-1 medications prescribed in 2025 include: Semaglutide (Wegovy, Ozempic) Tirzepatide (Mounjaro) Liraglutide (Saxenda) Peer-reviewed clinical trials published in journals such as The New England Journal of Medicine and JAMA document average body weight reductions of approximately 1022% over 612 months when GLP-1 medications are combined with lifestyle support and ongoing physician oversight
[1] In clinical studies, patients receiving clozapine plus adjunctive glycine experienced reduced antipsychotic benefit-likely owing to altered NMDA-receptor signaling
The basic patent requirement in EU SPC law requires that the SPC be based on a patent that protects the product
Ingredients: Water, Butylene Glycol, Niacinamide, 1,2-Hexanediol, Zea Mays (Corn) Starch, Chondrus Crispus Extract, Chlorella Vulgaris Extract, Saccharum Officinarum (Sugarcane) Extract, Centella Asiatica Leaf Extract, Chitosan, Malus Domestica Fruit Cell Culture Extract, Polyacrylate Crosspolymer-6, Betaine, Glucose, Acrylates/C10-30 Alkyl Acrylate Crosspolymer, Tromethamine, Acetyl Glucosamine, Fructooligosaccharides, Fructose, Glycerin, Pentylene Glycol, Ethylhexylglycerin, Allantoin, Dipropylene Glycol, Adenosine, Glutathione, Madecassoside, Hydroxypropyl Methylcellulose, Hydrogenated Lecithin, Beta-Glucan, Cholesterol, Asiaticoside, Ascorbic Acid, 3-O-Ethyl Ascorbic Acid, Ascorbyl Glucoside, Ceramide NP, Tocopherol, Ferulic Acid, Lactic Acid, Disodium EDTA, Carbomer, CI 77491
